Exicure, Inc.

Equities

XCUR

US30205M2008

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.5001 ^USD	-1.75%		-10.86%	-13.82%

Mar. 22	North American Morning Briefing : Stocks Struggle After New Records	DJ
Feb. 29	An unknown buyer agreed to acquire 39.3% stake in Exicure, Inc. from DGP Co.,Ltd. for KRW 6 billion.	CI

Thinking about buying stock in Exicure, Vaccinex, BioNano Genomics, Mind Medicine, or Matterport?

January 26, 2022 at 10:36 am EST

NEW YORK, Jan. 26, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XCUR, VCNX, BNGO, MNMD, and MTTR.

InvestorsObserver (PRNewsfoto/InvestorsObserver)

To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

XCUR: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=XCUR&prnumber=012620225
VCNX: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=VCNX&prnumber=012620225
BNGO: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=BNGO&prnumber=012620225
MNMD: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=MNMD&prnumber=012620225
MTTR: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?symbol=MTTR&prnumber=012620225

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.

InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.

View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-exicure-vaccinex-bionano-genomics-mind-medicine-or-matterport-301468784.html

SOURCE InvestorsObserver

Latest news about Exicure, Inc.

North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
An unknown buyer agreed to acquire 39.3% stake in Exicure, Inc. from DGP Co.,Ltd. for KRW 6 billion.	Feb. 28	CI
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis	Feb. 05	CI
Wall Street Set to Open Lower Friday; Employment Growth Tops Forecasts	Dec. 08	MT
Investors Look Ahead to Economic Indicators as US Futures Trend Lower in Friday's Premarket	Dec. 08	MT
Top Premarket Gainers	Dec. 08	MT
Northwestern University Notifies Exicure, Inc. that it Was Terminating the 2014 License	23-10-06	CI
Exicure, Inc. Appoints Minhee Eom to the Board	23-09-27	CI
Exicure Appoints New CEO, CFO	23-08-23	MT
Exicure, Inc. Announces Executive Changes	23-08-23	CI
Exicure, Inc. Announces Chief Financial Officer Changes	23-08-23	CI
Exicure, Inc. Announces Executive Changes	23-08-23	CI
Exicure Inc Provides Information to Shareholders	23-08-23	CI
North American Morning Briefing : China Trouble Hits Sentiment	23-08-18	DJ
Exicure, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
CBI Co Provides Information to Shareholders of Exicure Inc	23-08-08	CI
Exicure, Inc. Announces Resignation of Cheolho Jo from the Board and the Audit Committee	23-08-04	CI
Exicure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-07-14	CI
North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	23-06-23	DJ
North American Morning Briefing : Stock Futures -2-	23-06-16	DJ
North American Morning Briefing : Caution Ahead of Fed, Inflation Data to Hold Back Stocks	23-06-09	DJ
North American Morning Briefing : Stock Futures -2-	23-06-02	DJ
Exicure, Inc. Appoints Jung Sang as Chief Financial Officer	23-05-29	CI
Exicure, Inc. Appoints Jung Sang Kim as Chief Executive Officer	23-05-29	CI
Exicure, Inc. Appoints Jung Sang Kim as Class II Director	23-05-29	CI

Chart Exicure, Inc.

Duration

Period

More charts

Company Profile

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. It is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The Company focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.

Sector

Biotechnology & Medical Research

Calendar

2024-05-14 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
EXICURE, INC.	-13.82%	4.33M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

Exicure, Inc.

Equities

XCUR

US30205M2008

Biotechnology & Medical Research

Thinking about buying stock in Exicure, Vaccinex, BioNano Genomics, Mind Medicine, or Matterport?

Latest news about Exicure, Inc.

Chart Exicure, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs